PLTR at ~75x sales: how do you underwrite a switching-cost moat that a government is actively trying to test?

AI Summary

Summary

Palantir trades at ~75x trailing sales and ~53x 2026 guidance; author argues growth alone cannot justify this multiple.
The bull case relies on switching costs from Palantir’s Ontology model, but the NHS contract with a 2027 break clause is a live test of that moat.
Author believes the switching-cost moat is real, but the market is pricing it as permanent when it is contingent on no major customer successfully exiting.

Quality assessment: Well-researched DD with specific financials and a clearly defined catalyst, though the conclusion is deliberately cautious and forward-looking rather than a strong directional call.

Score 15

Comments 17

Upvote % 78%

▶ Full Post Text

Palantir's at roughly $430bn, about 75x trailing sales, \~53x on 2026 guidance of $8.15bn. FY25 revenue was $4.475bn, up 56%. Q2 2026 was up 93%, the fastest in company history. The top twenty customers each spent about $93.9m, up from $64.6m the year before, so the biggest accounts are expanding around 45% a year.

You can't justify that multiple on growth alone. You need to believe the revenue is unusually durable, which means believing the moat is real.

The moat argument is switching costs, and it's more specific than most software lock-in. Palantir doesn't sell a reporting layer over existing systems. They build what they call an Ontology, a formal model of what an organisation's objects are and how they relate, constructed by engineers working on site, and operational decisions then run through it. Nobody keeps a parallel copy, because the model *is* the product. So replacement isn't migration, it's reconstruction.

If that's true, retention should be near-total and net expansion should stay high, which is roughly what the customer numbers show.

What I’m still trying to figure out is... The NHS is the cleanest live test of that thesis. Palantir signed a £330m seven-year contract in 2023 with a break clause in 2027. As of January, 110 trusts were live or in delivery. In June a cross-party parliamentary committee recommended the government exercise that break clause. Separately, many of the largest English hospital trusts still hadn't adopted it despite central pressure.

So you have a customer with political motivation to leave, a contractual mechanism to leave, and a segment that never joined. If the moat holds there, it holds anywhere. If it doesn't, the multiple is resting on something softer than it looks.

My own view: I think the switching-cost argument is real but the market is pricing it as permanent when it's actually contingent on nobody testing it hard. 2027 is the test.

Disclosure, the video's mine and covers this in more depth: [https://www.youtube.com/watch?v=ldFcwL3vn1Y](https://www.youtube.com/watch?v=ldFcwL3vn1Y). Happy to discuss further.

Ideas

u/PuzzledBag931 Reddit r/ValueInvesting

PLTR trades at ~75x trailing sales / ~53x forward; top 20 customers are expanding ~45% annually, but valuation assumes extreme revenue durability. The NHS contract has a 2027 break clause and active political pressure to exit; a successful exit would undermine the switching-cost narrative and trigger multiple compression. Author is not calling a short because the moat is plausible, but sees asymmetric downside risk until the 2027 test resolves. NHS renews or expands Palantir usage; customer expansion continues; the Ontology switching costs hold as expected.

Summary

▶ Full Post Text

Ideas

More from Reddit — r/ValueInvesting